Abbott Laboratories Gestion

Gestion contrôle des critères 3/4

Le PDG Abbott Laboratories est Robert Ford, nommé en Oct2018, a un mandat de 6.08 ans. La rémunération annuelle totale est $ 23.27M, composée du salaire de 6.4% et des bonus 93.6%, y compris les actions et options de la société. détient directement 0.024% des actions de la société, d'une valeur de $ 48.95M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.5 ans et 5.8 ans.

Informations clés

Robert Ford

Directeur général

US$23.3m

Rémunération totale

Pourcentage du salaire du PDG	6.4%
Durée du mandat du directeur général	6.1yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	5.5yrs
Durée moyenne du mandat des membres du conseil d'administration	5.8yrs

Mises à jour récentes de la gestion

Recent updates

Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Oct 31

Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Oct 21

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Oct 14

Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Oct 11

Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Sep 27

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Sep 11

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Aug 16

Abbott Laboratories: Driving Value By Scaling Innovations

Aug 13

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Aug 05

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Jul 13

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Jul 01

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Jun 18

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26

Analyse de la rémunération des PDG

Comment la rémunération de Robert Ford a-t-elle évolué par rapport aux bénéfices de Abbott Laboratories?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Rémunération vs marché: La rémunération totale de Robert ($USD 23.27M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 12.67M ).

Rémunération et revenus: La rémunération de Robert a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Robert Ford (50 yo)

6.1yrs

Titularisation

US$23,268,171

Compensation

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Robert Ford	Chairman of the Board	6.1yrs	US$23.27m	0.024% $ 49.0m
Philip Boudreau	CFO & Executive VP of Finance	1.2yrs	US$3.32m	0.0023% $ 4.6m
Hubert Allen	Executive VP	11.8yrs	US$7.42m	0.011% $ 21.7m
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	10.2yrs	US$5.93m	0.0073% $ 14.7m
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.8yrs	US$5.50m	0.0035% $ 7.2m
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	pas de données	pas de données
Michael Comilla	Vice President of Investor Relations.	no data	pas de données	pas de données
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	pas de données	pas de données
Christopher Scoggins	Senior Vice President of Commercial Operations	1.8yrs	pas de données	pas de données
Mary Moreland	Executive Vice President of Human Resources	5.3yrs	pas de données	0.0059% $ 12.0m
Melissa Brotz	Senior Vice President of Global Marketing & External Affairs	no data	pas de données	pas de données
Jared Watkin	Executive Vice President of Diabetes Care	9.4yrs	pas de données	0.0042% $ 8.4m

5.5yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de ABT est chevronnée et expérimentée (5.5 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Robert Ford	Chairman of the Board	5yrs	US$23.27m	0.024% $ 49.0m
Daniel Starks	Independent Director	7.8yrs	US$349.29k	0.39% $ 786.8m
John Stratton	Independent Director	7.8yrs	US$341.96k	0.00020% $ 406.8k
Nancy McKinstry	Lead Independent Director	12.9yrs	US$405.96k	0.00027% $ 549.1k
Michael Roman	Independent Director	3.6yrs	US$337.96k	0% $ 0
Robert Alpern	Independent Director	16.1yrs	US$441.44k	0% $ 0
Michael O'Grady	Independent Director	1.6yrs	US$283.96k	0% $ 0
Michelle Kumbier	Independent Director	6.4yrs	US$331.96k	0.00018% $ 366.1k
Sally Blount	Independent Director	12.9yrs	US$362.60k	0.00015% $ 305.1k
Claire Babineaux-Fontenot	Independent Director	2.2yrs	US$354.96k	0% $ 0
Darren McDew	Independent Director	5.2yrs	US$331.19k	0% $ 0
Patricia Gonzalez	Independent Director	3.3yrs	US$356.96k	0% $ 0

5.8yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ABT sont considérés comme expérimentés (ancienneté moyenne 5.8 ans).

Abbott Laboratories Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Executive VP notifies of intention to sell stock

Chairman of the Board notifies of intention to sell stock

Executive Vice President of Finance notifies of intention to sell stock

Insider recently sold US$2.4m worth of stock

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Insider exercised options and sold US$2.6m worth of stock

Recent updates

Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

Executive VP notifies of intention to sell stock

Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Third quarter 2024 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Upcoming dividend of US$0.55 per share

Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Second quarter dividend of US$0.55 announced

Chairman of the Board notifies of intention to sell stock

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Driving Value By Scaling Innovations

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Second quarter 2024 earnings: EPS misses analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Upcoming dividend of US$0.55 per share

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

First quarter dividend of US$0.55 announced

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Why I Agree With Wall Street On This One

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

Executive Vice President of Finance notifies of intention to sell stock

New minor risk - Insider selling

Insider recently sold US$2.4m worth of stock

First quarter 2024 earnings: EPS exceeds analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

Fourth quarter dividend of US$0.55 announced

Now 20% overvalued after recent price rise

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Insider exercised options and sold US$2.6m worth of stock

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

The King Is Back: Abbott Laboratories' Path To >11% Annual Returns

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings: EPS exceeds analyst expectations

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi